The Latest Cardiac and Vascular News
Acquisition expands the Maxwell Biomedical product and intellectual property portfolio. SAN DIEGO, Dec. 14, 2022 /PRNewswire/ — Maxwell Biomedical announced today that it has completed the acquisition of Cardialen’s assets. Cardialen, a Minneapolis, MN based company developed MultiPulse™ Therapy (MPT™), a low-energy defibrillation and cardioversion therapy designed to treat atrial fibrillation (AFib) and ventricular tachycardia (VT). The Cardialen technology compliments […]
U.S. Food and Drug Administration approval of a clinical trial of Cardialen’s low-energy defibrillation and cardioversion therapy expands the number of leading clinical institutions evaluating its promising MultiPulse™ Therapy. MINNEAPOLIS–(BUSINESS WIRE)–Cardialen, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin a clinical trial of its MultiPulse™ […]
National Institutes of Health grant will support Cardialen’s development of its implantable, low-energy therapy designed to treat atrial fibrillation, a cardiac arrhythmia associated with debilitating shortness of breath, fatigue, pain, and an increased risk of stroke. MINNEAPOLIS–(BUSINESS WIRE)–Cardialen, Inc., has been awarded a $3 million National Institutes of Health (NIH) Phase IIb SBIR grant for […]
MultiPulse Therapy™ (MPT™) achieved 71% termination of acute, induced atrial fibrillation (AF) episodes at energy levels deemed to be tolerable for patients1,2 MINNEAPOLIS–(BUSINESS WIRE)–Cardialen, Inc., has published a first-in-human study in the Journal of the American College of Cardiology: Clinical Electrophysiology titled Novel Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation. The study consisted of 42 patients who […]
National Institutes of Health grant will support Cardialen’s development of its implantable, low-energy therapy designed to treat atrial fibrillation, a cardiac arrhythmia associated with debilitating shortness of breath, fatigue, pain, and an increased risk of stroke. MINNEAPOLIS–(BUSINESS WIRE)–Cardialen, Inc., has been awarded a $2.8 million National Institutes of Health (NIH) Phase II SBIR grant to […]
MINNEAPOLIS–(BUSINESS WIRE)–Cardialen, Inc., a medical device company developing a low-energy implantable defibrillation therapy designed to more gently restore normal heart rhythm, announced today the closing of a $17 million Series B investment led by RiverVest Venture Partners, along with Qiming Venture Partners, HBM Healthcare Investments and Cultivation Capital. The financing will be used to advance Cardialen’s […]
